Anifrolumab
Anifrolumab
Jump to navigation
Jump to search
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Interferon α/β receptor |
| Clinical data | |
| Routes of administration | Intravenous |
| ATC code |
|
| Identifiers | |
| CAS Number |
|
| ChemSpider |
|
| Chemical and physical data | |
| Formula | C6444H9964N1712O2018S44 |
| Molar mass | 145.12 kg/mol |
Anifrolumab[1] is a monoclonal antibody designed for the treatment of systemic lupus erythematosus.[2]
This drug was developed by MedImmune, which chose to move anifrolumab instead of sifalimumab into Phase III trials for lupus in 2015.[3][4][5]
Adverse effects[edit]
The most common adverse effect in the study was shingles, which occurred in 5% of patients in the low-dose group, to 10% in the high-dose group, and to 2% in the placebo group. Overall adverse effect rates were comparable in all groups.[6]
References[edit]
^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2)..mw-parser-output cite.citationfont-style:inherit.mw-parser-output qquotes:"""""""'""'".mw-parser-output code.cs1-codecolor:inherit;background:inherit;border:inherit;padding:inherit.mw-parser-output .cs1-lock-free abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-subscription abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registrationcolor:#555.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration spanborder-bottom:1px dotted;cursor:help.mw-parser-output .cs1-hidden-errordisplay:none;font-size:100%.mw-parser-output .cs1-visible-errorfont-size:100%.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-formatfont-size:95%.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-leftpadding-left:0.2em.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-rightpadding-right:0.2em
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Anifrolumab, American Medical Association.
^ "Press release: New Hope for Lupus Patients". MedImmune. 11 August 2015. Archived from the original on 31 July 2017.
^ "Anifrolumab". NHS Specialist Pharmacy Service. Retrieved 31 July 2017.
^ "Anifrolumab". AdisInsight. Retrieved 31 July 2017.
^ H. Spreitzer (29 August 2016). "Neue Wirkstoffe - Anifrolumab". Österreichische Apothekerzeitung (in German) (18/2016).
 | This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Drugs not assigned an ATC code
- Cutaneous lupus erythematosus
- Monoclonal antibodies
- Experimental drugs
- Monoclonal antibody stubs
(window.RLQ=window.RLQ||).push(function()mw.config.set("wgPageParseReport":"limitreport":"cputime":"0.572","walltime":"0.678","ppvisitednodes":"value":3759,"limit":1000000,"ppgeneratednodes":"value":0,"limit":1500000,"postexpandincludesize":"value":119435,"limit":2097152,"templateargumentsize":"value":1354,"limit":2097152,"expansiondepth":"value":14,"limit":40,"expensivefunctioncount":"value":1,"limit":500,"unstrip-depth":"value":1,"limit":20,"unstrip-size":"value":13046,"limit":5000000,"entityaccesscount":"value":1,"limit":400,"timingprofile":["100.00% 534.115 1 -total"," 69.50% 371.228 1 Template:Drugbox"," 45.03% 240.536 1 Template:Infobox"," 14.98% 80.035 16 Template:Unbulleted_list"," 14.36% 76.710 2 Template:Cite_journal"," 9.53% 50.922 9 Template:Navbox"," 7.72% 41.235 1 Template:Infobox_drug/chemical_formula"," 3.99% 21.312 1 Template:Monoclonals_for_immune_system"," 3.55% 18.971 1 Template:Cytokine_receptor_modulators"," 3.52% 18.775 3 Template:Cite_web"],"scribunto":"limitreport-timeusage":"value":"0.214","limit":"10.000","limitreport-memusage":"value":4266307,"limit":52428800,"cachereport":"origin":"mw1278","timestamp":"20181011014235","ttl":1900800,"transientcontent":false);mw.config.set("wgBackendResponseTime":89,"wgHostname":"mw1325"););
Clash Royale CLAN TAG